Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 민선준 | - |
dc.date.accessioned | 2024-05-16T00:25:02Z | - |
dc.date.available | 2024-05-16T00:25:02Z | - |
dc.date.issued | 2023-06-22 | - |
dc.identifier.citation | ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, v. 67, NO 6, Page. 1-13 | en_US |
dc.identifier.issn | 0066-4804 | en_US |
dc.identifier.issn | 1098-6596 | en_US |
dc.identifier.uri | https://information.hanyang.ac.kr/#/eds/detail?an=edselc.2-52.0-85163785971&dbId=edselc | en_US |
dc.identifier.uri | https://repository.hanyang.ac.kr/handle/20.500.11754/190300 | - |
dc.description.abstract | Benzoxaboroles are a new class of leucyl-tRNA synthetase inhibitors. Epetraborole, a benzoxaborole, is a clinical candidate developed for Gram-negative infections and has been confirmed to exhibit favorable activity against a well known pulmonary pathogen, Mycobacterium abscessus. However, according to ClinicalTrials.gov, in 2017, a clinical phase II study on the use of epetraborole to treat complicated urinary tract and intra-abdominal infections was terminated due to the rapid emergence of drug resistance during treatment. Nevertheless, epetraborole is in clinical development for nontuberculous mycobacteria (NTM) disease especially for Mycobacterium avium complex-related pulmonary disease (MAC-PD). DS86760016, an epetraborole analog, was further demonstrated to have an improved pharmacokinetic profile, lower plasma clearance, longer plasma half-life, and higher renal excretion than epetraborole in animal models. In this study, DS86760016 was found to be similarly active against M. abscessus in vitro, intracellularly, and in zebrafish infection models with a low mutation frequency. These results expand the diversity of druggable compounds as new benzoxaborole-based candidates for treating M. abscessus diseases. | en_US |
dc.description.sponsorship | This research was supported by grant 2020R1A2C1004077 from the National Research Foundation of South Korea, grant from 2020ER520601 the Korea Disease Control and Prevention Agency (2020 to 2021), and grant HI22C0884 from the Korea Health Industry Development Institute. T.Q.N., B.T.B.H., Y.P., B.E.H., S.J., and A.C. were supported by the BK21 Four Program. | en_US |
dc.language | en_US | en_US |
dc.publisher | AMER SOC MICROBIOLOGY | en_US |
dc.relation.ispartofseries | v. 67, NO 6;1-13 | - |
dc.subject | Mycobacterium abscessus | en_US |
dc.subject | leucyl-tRNA | en_US |
dc.subject | benzoxaboroles | en_US |
dc.subject | epetraborole | en_US |
dc.subject | DS86760016 | en_US |
dc.subject | mutation frequency | en_US |
dc.subject | drug resistance | en_US |
dc.title | DS86760016, a Leucyl-tRNA Synthetase Inhibitor, Is Active against Mycobacterium abscessus | en_US |
dc.type | Article | en_US |
dc.relation.no | 6 | - |
dc.relation.volume | 67 | - |
dc.identifier.doi | 10.1128/aac.01567-22 | en_US |
dc.relation.page | 1-13 | - |
dc.relation.journal | ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | - |
dc.contributor.googleauthor | Nguyen, Thanh Quang | - |
dc.contributor.googleauthor | Heo, Bo Eun | - |
dc.contributor.googleauthor | Hanh, Bui Thi Bich | - |
dc.contributor.googleauthor | Jeon, Seunghyeon | - |
dc.contributor.googleauthor | Park, Yujin | - |
dc.contributor.googleauthor | Choudhary, Arunima | - |
dc.contributor.googleauthor | Lee, Sujin | - |
dc.contributor.googleauthor | Kim, Tae Ho | - |
dc.contributor.googleauthor | Moon, Cheol | - |
dc.contributor.googleauthor | Min, Sun-Joon | - |
dc.relation.code | 2023041087 | - |
dc.sector.campus | E | - |
dc.sector.daehak | COLLEGE OF SCIENCE AND CONVERGENCE TECHNOLOGY[E] | - |
dc.sector.department | DEPARTMENT OF CHEMICAL AND MOLECULAR ENGINEERING | - |
dc.identifier.pid | sjmin | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.